STAT+: Biotech VCs, used to a winning formula in drug development, face disruption
Why it matters: The disruption impacts how billions of dollars are invested in developing new medicines.
- Venture capitalists have historically relied on a consistent and profitable strategy for biotech investments.
- That approach is currently undergoing substantial disruption, challenging established norms in drug development funding.
Biotech venture capitalists are facing a significant disruption to their long-standing, successful investment formula in drug development. This shift challenges the traditional recipe that has generated substantial returns for decades, forcing VCs to adapt to new market dynamics.
